JEFFERIES 2014: Abiomed sees growth beyond Impella approval
This article was originally published in Clinica
Executive Summary
The upcoming expected US premarket approval (PMA) of Abiomed’s Impella 2.5 percutaneous heart pump will set up an extended growth cycle for the company as more product approvals follow in its wake. That was the conclusion of analyst Raj Denhoy following the Jefferies healthcare conference held in London on 19-20 November.